Graham D. Neil
Director of Finance/CFO at HealthHub Patient Engagement Solutions, Inc.
Graham D. Neil active positions
| Companies | Position | Start | End |
|---|---|---|---|
HealthHub Patient Engagement Solutions, Inc.
 HealthHub Patient Engagement Solutions, Inc. Specialty TelecommunicationsCommunications HealthHub Patient Engagement Solutions provides interactive patient entertainment systems. It directly involves in the design and development of interactive patient entertainment systems, including TV and phone rental systems, automated closed circuit education delivery systems, and new flat screen LCD TV products. The company was founded by Alan Arthur Simpson in 1967 and is headquartered in Regina, Canada. | Director of Finance/CFO | 2022-05-31 | - |
| Chief Executive Officer | 2022-01-31 | 2022-05-31 |
Career history of Graham D. Neil
Former positions of Graham D. Neil
| Companies | Position | Start | End |
|---|---|---|---|
| INTELLIPHARMACEUTICS INTERNATIONAL INC. | Chief Administrative Officer | 2009-12-16 | 2010-02-14 |
| Director of Finance/CFO | 2009-12-16 | 2010-11-25 | |
| Public Communications Contact | 2009-12-16 | 2010-11-25 | |
Vasogen, Inc.
 Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Director of Finance/CFO | 1998-12-31 | 2009-07-13 |
Statistics
International
| Canada | 4 |
Operational
| Director of Finance/CFO | 3 |
| Chief Administrative Officer | 1 |
| Public Communications Contact | 1 |
Sectoral
| Health Technology | 3 |
| Communications | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| INTELLIPHARMACEUTICS INTERNATIONAL INC. | Health Technology |
| Private companies | 2 |
|---|---|
Vasogen, Inc.
Vasogen, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activities are research and commercialization of therapies designed to target the destructive inflammatory process associated with the development and progression of cardiovascular and neurodegenerative disorders. It's lead product, the Celacade System, is designed to activate the immune response to apoptosis - an important physiological process that regulates inflammation. Celacade has received European regulatory approval under the CE Mark for chronic heart failure and is currently being marketed in Europe by Grupo Ferrer Internacional, S.A. Celacade is also in late-stage development for the treatment of chronic heart failure in the United States. It is also developing a new class of drugs for the treatment of certain neuro-inflammatory disorders. VP025 is the lead drug candidate from this new class. | Health Technology |
HealthHub Patient Engagement Solutions, Inc.
HealthHub Patient Engagement Solutions, Inc. Specialty TelecommunicationsCommunications HealthHub Patient Engagement Solutions provides interactive patient entertainment systems. It directly involves in the design and development of interactive patient entertainment systems, including TV and phone rental systems, automated closed circuit education delivery systems, and new flat screen LCD TV products. The company was founded by Alan Arthur Simpson in 1967 and is headquartered in Regina, Canada. | Communications |
- Stock Market
- Insiders
- Graham D. Neil
- Experience
